Anifrolumab demonstrated sustained, numerically greater improvements in patient-reported outcomes (PROs) compared to placebo over 4 years in moderate-to-severe systemic lupus erythematosus (SLE).
Key domains showing benefit included bodily pain and mental health, as measured by SF-36v2, as well as health utility indices (SF-6D, EQ-5D-5L).
These benefits occurred in the context of improved disease activity, reduced glucocorticoid requirements, and a tolerable safety profile.
The TULIP-LTE study supports the long-term use of anifrolumab as an effective option to enhance health-related quality of life in SLE.
